de Boer M - Search Results

1

Humanized anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells.

van Neerven RJ, van Roomen CP, Thomas WR, de Boer M, Knol EF, Davis FM. van Neerven RJ, et al. Among authors: de boer m. Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):400-2. doi: 10.1159/000053770. Int Arch Allergy Immunol. 2001. PMID: 11307028

2

Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression.

Van Neerven RJ, Van de Pol MM, Van der Zee JS, Stiekema FE, De Boer M, Kapsenberg ML. Van Neerven RJ, et al. Among authors: de boer m. Clin Exp Allergy. 1998 Jul;28(7):808-16. doi: 10.1046/j.1365-2222.1998.00306.x. Clin Exp Allergy. 1998. PMID: 9720814

3

Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.

Kwekkeboom J, de Rijk D, Kasran A, Barcy S, de Groot C, de Boer M. Kwekkeboom J, et al. Among authors: de rijk d, de boer m, de groot c. Eur J Immunol. 1994 Mar;24(3):508-17. doi: 10.1002/eji.1830240303. Eur J Immunol. 1994. PMID: 7510232

4

CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.

Kwekkeboom J, De Boer M, Tager JM, De Groot C. Kwekkeboom J, et al. Among authors: de boer m, de groot c. Immunology. 1993 Jul;79(3):439-44. Immunology. 1993. PMID: 7691726 Free PMC article.

5

Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells.

van Dijk AM, Otten HG, Vercauteren SM, Kessler FL, de Boer M, Verdonck LF, de Gast GC. van Dijk AM, et al. Among authors: de gast gc, de boer m. Eur J Immunol. 1996 Sep;26(9):2275-8. doi: 10.1002/eji.1830260946. Eur J Immunol. 1996. PMID: 8814278

6

Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses.

Boon L, Brok HP, Bauer J, Ortiz-Buijsse A, Schellekens MM, Ramdien-Murli S, Blezer E, van Meurs M, Ceuppens J, de Boer M, 't Hart BA, Laman JD. Boon L, et al. Among authors: de boer m. J Immunol. 2001 Sep 1;167(5):2942-9. doi: 10.4049/jimmunol.167.5.2942. J Immunol. 2001. PMID: 11509643

7

Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys.

Boon L, Laman JD, Ortiz-Buijsse A, den Hartog MT, Hoffenberg S, Liu P, Shiau F, de Boer M. Boon L, et al. Among authors: de boer m. Toxicology. 2002 May 15;174(1):53-65. doi: 10.1016/s0300-483x(02)00057-4. Toxicology. 2002. PMID: 11972992

8

Requirements for the generation of memory B cells in vivo and their subsequent activation in vitro for the production of antigen-specific hybridomas.

De Boer M, Ten Voorde GH, Ossendorp FA, Van Duijn G, Tager JM. De Boer M, et al. J Immunol Methods. 1988 Oct 4;113(1):143-9. doi: 10.1016/0022-1759(88)90390-0. J Immunol Methods. 1988. PMID: 2459251

9

Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation.

Kuiper H, Brouwer M, de Boer M, Parren P, van Lier RA. Kuiper H, et al. Among authors: de boer m. Eur J Immunol. 1994 Sep;24(9):1956-60. doi: 10.1002/eji.1830240903. Eur J Immunol. 1994. PMID: 7522154

10

FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.

Barcy S, Wettendorff M, Leo O, Urbain J, Kruger M, Ceuppens JL, de Boer M. Barcy S, et al. Among authors: de boer m. Int Immunol. 1995 Feb;7(2):179-89. doi: 10.1093/intimm/7.2.179. Int Immunol. 1995. PMID: 7537534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,782 results

Search Page

Filters